Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development

 Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business
                                 Development

Company to explore commercial partnerships for its lead product, Oxycodone
DETERx® (COL-003), an abuse-deterrent, extended-release product for chronic
pain

PR Newswire

CANTON, Mass., April 3, 2013

CANTON, Mass., April 3, 2013 /PRNewswire/ --Collegium Pharmaceutical, Inc., a
specialty pharmaceutical company focused on the development of innovative
treatments for chronic pain, has hired Douglas Carlson in the newly-created
position of Vice President of Business Development.

Doug previously held the position of Senior Director, Business Development at
BTG International Inc., where he was responsible for global specialty
pharmaceutical M&A and licensing. Prior to BTG International, Doug spent
nearly five years at Ovation Pharmaceuticals, Inc. where he advanced from
Manager of Business Development to Senior Director of Corporate Business
Development and Strategy, and played a pivotal role in the sale of Ovation to
H. Lundbeck A/S resulting in a $900 million acquisition. Prior to Ovation,
Doug was an Associate in the healthcare group at Pequot Ventures, the venture
capital arm of Pequot Capital Management, Inc. Doug started his career in the
healthcare investing banking group SG Cowen & Co. He received a Bachelor of
Arts degree in American Studies from Trinity College in Hartford, Connecticut
and completed a post-graduate advanced studies program at Oxford University.

"Collegium's lead development program, Oxycodone DETERx^®, leverages the
Company's abuse-deterrent technology platform in an area with significant
unmet medical need. I am incredibly excited to be joining Collegium as the
Company brings its first product closer to FDA approval," states Doug
Carlson. 

"As we rapidly advance Oxycodone DETERx^® towards an NDA filing within the
next 12 months, we will be initiating a process to identify potential
commercial partners for both the U.S. and international markets. We are
excited to have a person with Doug's experience and background joining the
team at this important time for the Company," states Michael Heffernan, CEO of
Collegium.

About DETERx^® Technology

The DETERx^® drug delivery platform consists of a multi-particulate matrix
formulation in a capsule. While developed primarily to provide abuse-deterrent
properties to protect against common methods of tampering such as chewing,
crushing, insufflation and extraction for IV injection, the multi-particulate
design is expected to enable patients with difficulty swallowing to open the
capsule and administer the contents on food or via a gastronomy tube, while
maintaining the extended-release properties of the product. DETERx^®
technology can be used with drugs that are commonly abused such as opioids and
amphetamines, as well as drugs that have narrow therapeutic windows that would
benefit from protection against misuse such as breaking, crushing, grinding or
dissolving the product. The formulation platform is covered by U.S. and
international patents and patent applications. COL-003 is the first of a
number of product candidates using the DETERx^® platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused
on developing a portfolio of products that incorporate its patent-protected
DETERx^® formulation platform for the treatment of chronic pain. The DETERx^®
oral drug delivery technology provides extended-release delivery, unique
abuse-deterrent properties, and flexible dose administration options. For more
information, visit the Company's website at www.collegiumpharma.com.

Contact:

Michael Heffernan, President
Collegium Pharmaceutical, Inc.
781.713.3699
mheffernan@collegiumpharma.com

SOURCE Collegium Pharmaceutical, Inc.

Website: http://www.collegiumpharma.com
 
Press spacebar to pause and continue. Press esc to stop.